Consider it a success case or a bright point of discovery in the search for cancer inhibitors. An international team of researchers has identified a new compound to potentially disarm AKR1C3, an upregulated enzyme found in prostate, breast and other cancers, using AI-based drug screening and brilliant X-ray light at MAX IV. Is this study a diamond in the rough or a glimpse of more to come in biomedical research using artificial intelligence?
